Breakthrough Invasive Fungal Infection After Coadministration of Venetoclax and Voriconazole

Venetoclax requires a 75% dose reduction when coadministered with voriconazole. In a 10-year historical cohort of treatment with venetoclax, we did not observe a worse hematologic outcome in patients who received voriconazole prophylaxis versus those who did not. Subtherapeutic voriconazole levels a...

Descripción completa

Detalles Bibliográficos
Autores principales: Hall, Victoria G, Tang, Kenny, Kumar, Deepali, Rotstein, Coleman, Chow, Signy, Chan, Steven M, Husain, Shahid, Hosseini-Moghaddam, Seyed M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10064263/
https://www.ncbi.nlm.nih.gov/pubmed/37008567
http://dx.doi.org/10.1093/ofid/ofad134
_version_ 1785017866242752512
author Hall, Victoria G
Tang, Kenny
Kumar, Deepali
Rotstein, Coleman
Chow, Signy
Chan, Steven M
Husain, Shahid
Hosseini-Moghaddam, Seyed M
author_facet Hall, Victoria G
Tang, Kenny
Kumar, Deepali
Rotstein, Coleman
Chow, Signy
Chan, Steven M
Husain, Shahid
Hosseini-Moghaddam, Seyed M
author_sort Hall, Victoria G
collection PubMed
description Venetoclax requires a 75% dose reduction when coadministered with voriconazole. In a 10-year historical cohort of treatment with venetoclax, we did not observe a worse hematologic outcome in patients who received voriconazole prophylaxis versus those who did not. Subtherapeutic voriconazole levels and a triazole exposure history may contribute to breakthrough invasive fungal infection.
format Online
Article
Text
id pubmed-10064263
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-100642632023-04-01 Breakthrough Invasive Fungal Infection After Coadministration of Venetoclax and Voriconazole Hall, Victoria G Tang, Kenny Kumar, Deepali Rotstein, Coleman Chow, Signy Chan, Steven M Husain, Shahid Hosseini-Moghaddam, Seyed M Open Forum Infect Dis Brief Report Venetoclax requires a 75% dose reduction when coadministered with voriconazole. In a 10-year historical cohort of treatment with venetoclax, we did not observe a worse hematologic outcome in patients who received voriconazole prophylaxis versus those who did not. Subtherapeutic voriconazole levels and a triazole exposure history may contribute to breakthrough invasive fungal infection. Oxford University Press 2023-03-16 /pmc/articles/PMC10064263/ /pubmed/37008567 http://dx.doi.org/10.1093/ofid/ofad134 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Brief Report
Hall, Victoria G
Tang, Kenny
Kumar, Deepali
Rotstein, Coleman
Chow, Signy
Chan, Steven M
Husain, Shahid
Hosseini-Moghaddam, Seyed M
Breakthrough Invasive Fungal Infection After Coadministration of Venetoclax and Voriconazole
title Breakthrough Invasive Fungal Infection After Coadministration of Venetoclax and Voriconazole
title_full Breakthrough Invasive Fungal Infection After Coadministration of Venetoclax and Voriconazole
title_fullStr Breakthrough Invasive Fungal Infection After Coadministration of Venetoclax and Voriconazole
title_full_unstemmed Breakthrough Invasive Fungal Infection After Coadministration of Venetoclax and Voriconazole
title_short Breakthrough Invasive Fungal Infection After Coadministration of Venetoclax and Voriconazole
title_sort breakthrough invasive fungal infection after coadministration of venetoclax and voriconazole
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10064263/
https://www.ncbi.nlm.nih.gov/pubmed/37008567
http://dx.doi.org/10.1093/ofid/ofad134
work_keys_str_mv AT hallvictoriag breakthroughinvasivefungalinfectionaftercoadministrationofvenetoclaxandvoriconazole
AT tangkenny breakthroughinvasivefungalinfectionaftercoadministrationofvenetoclaxandvoriconazole
AT kumardeepali breakthroughinvasivefungalinfectionaftercoadministrationofvenetoclaxandvoriconazole
AT rotsteincoleman breakthroughinvasivefungalinfectionaftercoadministrationofvenetoclaxandvoriconazole
AT chowsigny breakthroughinvasivefungalinfectionaftercoadministrationofvenetoclaxandvoriconazole
AT chanstevenm breakthroughinvasivefungalinfectionaftercoadministrationofvenetoclaxandvoriconazole
AT husainshahid breakthroughinvasivefungalinfectionaftercoadministrationofvenetoclaxandvoriconazole
AT hosseinimoghaddamseyedm breakthroughinvasivefungalinfectionaftercoadministrationofvenetoclaxandvoriconazole

Ejemplares similares